Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents.

by jmiller on September 9, 2015

Article concludes:  The ginkgo biloba is an effective and safe complementary tratment for ADHD.  It resulted in significant increase in overall clinical treatment response.  (Complementary Therapies in Clinical Pracitice, August)  Click here to read full-text.… learn more

Osteoporosis: the emperor has no clothes

by jmiller on September 9, 2015

Article concludes: “The evidence for the viability of bone-targeted pharmacotherapy in preventing hip fracture and other clinical fragility fractures is mainly limited to women aged 65-80 years with osteoporosis, whereas the proof of hip fracture-preventing efficacy in women over 80 … learn more

An official ATS/AACN/ACCP/ESICM/SCCM policy statement: responding to requests for potentially inappropriate treatments in Intensive Care Units

by jmiller on July 16, 2015

“The multisociety statement on responding to requests for potentially inappropriate treatments in intensive care units provides guidance for clinicians to prevent and manage disputes in patients with advanced critical illness.”   (Am J Resp Crit Care Med, June 1)   Click here learn more

How slow is too slow? Correlation of operative time to complications? An analysis from the Tennessee Surgical Quality Collaborative

by jmiller on July 16, 2015

“Duration of operation correlates with complications and time longer than a statewide established standard carries higher risk.  to reduce risk of complications, these data support expeditious surgical technique and preoperative pulmonary training, and offer accurate outcomes assessment for patient counseling … learn more

Breast cancer screening, incidence, and mortality across US counties

by jmiller on July 16, 2015

“When analyzed at the county level, the clearest result of mammography screening is the diagnosis of additional small cancers.  Furthermore, there is no conocomitant decline in the detection of larger cancers, which might explain the absence of any significant difference … learn more

Edoxaban (Savaysa) – The Fourth New Oral Anticoagulant

by jmiller on July 16, 2015

“The FDA has approved edoxaban (Savaysa), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromboembolism (VTE) and for prevention of stroke and systematic embolism in patients with nonvalvular atrial fibrillation.  It is the fourth new oral anticoagulant … learn more

NEW DATABASE – Used in conjunction with UpToDate – VisualDX

by jmiller on July 9, 2015

What is VisualDx?

VisualDx is one of the most widely used medical apps in the world to improve diagnostic accuracy,  medical education  and patient education.   VisualDx is already licensed by more than 50% of US medical schools including Harvard, Yale, … learn more

Innovation in maternal-fetal therapy: a positon statement of the NA Fetal Therapy Network and Expanded carrier screening in reproductive medicine – points to consider: A joint statement

by jmiller on June 26, 2015

Innovative medical therapy often occupies an uncomfortable space between formal research and established clinical practice..  Because fetal medicine is unique in that other fields do not have to consider the well being of two individuals at the same time, the … learn more

Older posts «